SRR1313121
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ESTROGEN_RESPONSE_EARLY+0.450
- PROTEIN_SECRETION+0.430
- ANDROGEN_RESPONSE+0.380
- ESTROGEN_RESPONSE_LATE+0.350
- UV_RESPONSE_DN+0.320
- APICAL_SURFACE+0.300
- ANGIOGENESIS+0.220
- MITOTIC_SPINDLE+0.210
- HEME_METABOLISM+0.180
- PI3K_AKT_MTOR_SIGNALING+0.170
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.520
- MYC_TARGETS_V2-0.400
- INTERFERON_GAMMA_RESPONSE-0.370
- IL6_JAK_STAT3_SIGNALING-0.350
- INFLAMMATORY_RESPONSE-0.330
- INTERFERON_ALPHA_RESPONSE-0.310
- KRAS_SIGNALING_UP-0.210
- HEDGEHOG_SIGNALING-0.180
- TNFA_SIGNALING_VIA_NFKB-0.170
- COMPLEMENT-0.150
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-A1-A0SE-01A-11R-A084-07 | — | A | 0.804 |
| 2 | BSR_19_0079_A1_S53 | — | B | 0.794 |
| 3 | SRR1313124 | — | B | 0.764 |
| 4 | TCGA-AR-A1AV-01A-21R-A12P-07 | — | B | 0.748 |
| 5 | SRR1313090 | — | B | 0.746 |
| 6 | TCGA-A8-A08O-01A-21R-A056-07 | — | B | 0.744 |
| 7 | TCGA-AN-A0FZ-01A-11R-A034-07 | — | B | 0.737 |
| 8 | TCGA-B6-A0WT-01A-11R-A109-07 | — | B | 0.736 |
| 9 | TCGA-D8-A1X7-01A-11R-A14M-07 | — | B | 0.732 |
| 10 | SRR25617914 | — | C | 0.728 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ESTROGEN_RESPONSE_EARLY | 0.450 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.430 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.380 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.350 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.320 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.300 | Temsirolimus | — uncovered |
| ANGIOGENESIS | 0.220 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.210 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.180 | Temsirolimus | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.170 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.170 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.150 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.150 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.120 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.120 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.110 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.110 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.100 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.080 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.070 | Inavolisib | — uncovered |